



# FINDING BALANCE

in the Treatment of **Bipolar I Disorder** and **Schizophrenia**.

## About the Program

Despite a wealth of antipsychotic treatment options in Canada, many important gaps persist in the management of both bipolar I disorder (BPI) and schizophrenia (SZ).

Please join your peers for an informative and interactive session focusing on the addition of a new agent to the antipsychotic armamentarium.

## At the conclusion of the session, participants will be able to:

- ◇ Identify current unmet needs for patients with:
- ◇ Explain similarities, differences, and potential clinical implications of cariprazine's pharmacologic characteristics relative to previously approved 2<sup>nd</sup> and 3<sup>rd</sup>-generation antipsychotics.
- ◇ Describe the efficacy and safety of cariprazine in clinical trials in:
- ◇ Define the place of cariprazine in clinical practice among patients with:

## RSVP to

Email

Phone

By

DATE

TIME

SPEAKER

LOCATION

## Program developed by

### HOWARD MARGOLESE

MD, CM, MSc, FRCPC  
Montreal, QC

### DIANE MCINTOSH

BSc Pharm, MD, FRCPC  
Vancouver, BC

### ROGER MCINTYRE

MD, FRCPC  
Toronto, ON

### RIC PROCYSHYN

MSc, Pharm. D, PhD  
Vancouver, BC